OncoZenge AB Company Description

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden.

It offers BupiZenge, which has completed Phase 2 clinical trial for the treatment of pain in the oral cavity.

The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

OncoZenge AB (publ)

Country	Sweden
Founded	2020
Industry	Biotechnology
Sector	Healthcare
Employees	2
CEO	Stian Kildal

Contact Details

Address: Gustavslundsvägen 34 Bromma, 167 51 Sweden
Phone	46 8 31 14 20
Website	oncozenge.com

Stock Details

Ticker Symbol	ONCOZ
Exchange	Nasdaq Stockholm
Fiscal Year	January - December
Reporting Currency	SEK
ISIN Number	SE0015504097
SIC Code	2834

Key Executives

Name	Position
Stian Kildal	Chief Executive Officer
Michael Owens B.A., B.S., B.S.B.A	Chief Financial Officer
Ida Sparrfeldt	Chief Auditor